Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis
Status:
Completed
Trial end date:
2010-02-08
Target enrollment:
Participant gender:
Summary
This is an open-label, one arm, single institution study. Arsenic trioxide [TrisenoxTM
Injection], 0.25mg/kg/dose administered intravenously over 2 hours.
20 patients
Complete remission, partial remission, clinical improvement, progressive disease, stable
disease, relapse (per IWG consensus criteria, 2006) Clinical chemistry, hematology and ECGs
will be assessed at least weekly during study treatments. Adverse events will be assessed in
accordance with the NCI Common Toxicity Criteria, Version 2 at each study visit.